Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial (Q49142379)

18 February 2018

title

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial (English)

1 reference

18 February 2018

main subject

edoxaban

1 reference

ChEBI release 2020-05-28

1 reference

Eugene Braunwald

1 reference

18 February 2018

Robert P Giugliano

0 references

Elliott M Antman

1 reference

18 February 2018

Marc S Sabatine

1 reference

18 February 2018

Sabina A Murphy

Sabina A Murphy

1 reference

18 February 2018

Christian C Ruff

Christian T Ruff

1 reference

18 February 2018

Naveen Deenadayalu

Naveen Deenadayalu

1 reference

18 February 2018

Michele F Mercuri

Michele F Mercuri

1 reference

18 February 2018

Francesco Nordio

Francesco Nordio

1 reference

18 February 2018

Jessica L. Mega

Jessica L Mega

1 reference

18 February 2018

author name string

Joseph R Walker

1 reference

18 February 2018

Alexander G Vandell

1 reference

18 February 2018

James Lee

1 reference

18 February 2018

language of work or name

English

0 references

publication date

11 March 2015

1 reference

18 February 2018

number of pages

1 reference

inferred from page(s)

published in

The Lancet

1 reference

18 February 2018

volume

385

1 reference

18 February 2018

issue

9984

1 reference

18 February 2018

page(s)

2280-2287

1 reference

18 February 2018

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

National surveillance of emergency department visits for outpatient adverse drug events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Pharmacogenetics and coumarin dosing--recalibrating expectations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Genetic determinants of dabigatran plasma levels and their relation to bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Edoxaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A randomized trial of genotype-guided dosing of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Genetic determinants of response to warfarin during initial anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Estimation of the warfarin dose with clinical and pharmacogenetic data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Genetic risk factors for major bleeding in patients treated with warfarin in a community setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

A pharmacogenetic versus a clinical algorithm for warfarin dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Effect of study setting on anticoagulation control: a systematic review and metaregression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961994-2

7 January 2021

10.1016/S0140-6736(14)61994-2

Identifiers

DOI

1 reference

18 February 2018

release_ruten2tsorcnfc75ipto6nfwxy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ruten2tsorcnfc75ipto6nfwxy

24 November 2022

mapped directly with Wikidata item

1 reference

18 February 2018